MORRIS PLAINS, N.J., April 13, 2009 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that nine presentations on the Company's potential products will occur at the 100th Annual Meeting of the American Association for Cancer Research (AACR), April 18 - 22, 2009, in Denver, Colorado. Five of the presentations will be on product candidates created by the Company, and its majority-owned subsidiary, IBC Pharmaceuticals, Inc.'s proprietary protein engineering platform technology known as Dock-and-Lock (DNL). The schedule and meeting places for the poster sessions, together with the abstract and poster board numbers are listed below:
* "Milatuzumab (humanized anti-CD74 mAb) targets and kills B-cell malignancies, and blocks signal transduction through CD74" (Abstract No. 1228, Session Title: Antibody and Antibody Targets, Sunday, April 19, 1:00 p.m. - 5:00 p.m., Poster Board #2, Hall B-F) * "Multiple signaling pathways of hexavalent anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized monoclonal antibodies correlate with improved anti-lymphoma properties" (Abstract No. 1229, Session Title: Antibody and Antibody Targets, Sunday, April 19, 1:00 p.m. - 5:00 p.m., Poster Board #3, Hall B-F) * "HLA-DR as a target for therapy of human and canine B-cell malignancies" (Abstract No. 1255, Session Title: Antibody and Antibody Targets, Sunday, April 19, 1:00 p.m. - 5:00 p.m., Poster Board #29, Hall B-F) * "Targeted therapy of human colonic, lung, and pancreatic cancer xenografts, growing in nude mice, with potent antibody conjugates of SN-38" (Abstract No. 3233, Session Title: Immunotoxins, Immunoconjugates, and Antibody Combinations, Tuesday, April 21, 8:00 a.m. - 12:00 p.m., Poster Board #1, Hall B-F) * "A veltuzumab-IFNa2b conjugate with potent in vitro and in vivo anti-lymphoma activity" (Abstract No. 3237, Session Title: Immunotoxins, Immunoconjugates, and Antibody Combinations, Tuesday, April 21, 8:00 a.m. - 12:00 p.m., Poster Board #5, Hall B-F) * "Tetrameric erythropoietin anchored on IgG with improved biological activity" (Abstract No. 3255, Session Title: Immunotoxins, Immunoconjugates, and Antibody Combinations, Tuesday, April 21, 8:00 a.m. - 12:00 p.m., Poster Board #22, Hall B-F) * "Generation of a novel class of tetrameric granulocyte colony-stimulating factor with improved biological activity" (Abstract No. 3256, Session Title: Immunotoxins, Immunoconjugates, and Antibody Combinations, Tuesday, April 21, 8:00 a.m. - 12:00 p.m., Poster Board #23, Hall B-F) * "Improved pharmacokinetics, anti-viral and anti-lymphoma activity of site-specifically pegylated, dimeric, interferon-a2b made by the dock-and-lock (DNL) method" (Abstract No. 5062, Session Title: Cytokines, Immune Modulation, and Immune Monitoring, Wednesday, April 22, 8:00 a.m. - 12:00 p.m., Poster Board #4, Hall B-F) * "Expression of CD74 in pancreatic and colorectal carcinomas as a basis for milatuzumab immunotherapy" (Abstract No. 5485, Session Title: Antibody Technologies, Wednesday, April 22, 8:00 a.m. - 12:00 p.m., Poster Board #25, Hall B-F)
About Immunomedics
Immunomedics is a New Jersey-based biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. We have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or "naked" form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create highly targeted agents. Using these technologies, we have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. We also have a majority ownership in IBC Pharmaceuticals, Inc., which is developing a novel Dock-and-Lock (DNL) methodology with us for making fusion proteins and multifunctional antibodies, and a new method of delivering imaging and therapeutic agents selectively to disease, especially different solid cancers (colorectal, lung, pancreas, etc.), by proprietary, antibody-based, pretargeting methods. We believe that our portfolio of intellectual property, which includes approximately 134 patents issued in the United States and more than 300 other patents issued worldwide, protects our product candidates and technologies. For additional information on us, please visit our website at www.immunomedics.com. The information on our website does not, however, form a part of this press release.
This release, in addition to historical information, may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials, out-licensing arrangements (including the timing and amount of contingent payments), forecasts of future operating results, and capital raising activities, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, risks associated with new product development (including clinical trials outcome and regulatory requirements/actions), our dependence on our licensing partners for the further development of epratuzumab for autoimmune indications and veltuzumab for non-cancer indications, competitive risks to marketed products and availability of required financing and other sources of funds on acceptable terms, if at all, as well as the risks discussed in the Company's filings with the Securities and Exchange Commission. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.